Status:
COMPLETED
Association of Serum Eotaxin Levels and Markers of Myocardiac Injury in Hemodialysis Patients
Lead Sponsor:
Tungs' Taichung Metroharbour Hospital
Conditions:
Myocardium; Injury
Coronary Artery Disease
Eligibility:
All Genders
20+ years
Brief Summary
Background: Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality among dialysis patients. Eotaxin-1(also known as Eotaxin and CCL11), an eosinophil-specific chemoattra...
Detailed Description
Study Design and Patient Population This cross-sectional trial, and will be carried out in accordance with the Declaration of Helsinki and applicable regulations. The protocol will be sent to the inst...
Eligibility Criteria
Inclusion
- Both sexes aged 20 years or over
- Received stable hemodialysis at least 3 months.
- Written informed consent.
Exclusion
- acute infection or malignancy
Key Trial Info
Start Date :
May 2 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
291 Patients enrolled
Trial Details
Trial ID
NCT06211244
Start Date
May 2 2024
End Date
December 31 2024
Last Update
June 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tungs' Taichung MetroHarbour Hospital
Taichung, Taiwan